β-hydroxybutyrate as a biomarker of β-cell function in new-onset type 2 diabetes and its association with treatment response at 6 months
Authors' conclusion
In patients with newly diagnosed T2D, a higher initial βHB level was a significant predictive marker of greater glycemic improvement after antidiabetic treatment, despite its associations with hyperglycemia and decreased insulin secretion at baseline.
Study context
- Population
- Patients with newly diagnosed drug-naïve T2D, 2017 to 20214 βHB groups
- Participants
- 369 patients
- Exposure
- Higher vs lower initial serum βHB groups
- Outcome
- Glycemic and insulin secretory indices at diagnosis; HbA1c improvement at 6 months
Main finding
As reported in the abstract
- Higher serum βHB group associated with higher glycemic parameters including HbA1c and lower insulin secretory indices at diagnosis
- Higher serum βHB group was an independent determinant of greater relative improvement in HbA1c after 6 months of anti-diabetic treatment, regardless of drug type
Observational data: associations, not effects.
Further findings
- Higher serum βHB group more likely to have well-controlled HbA1c (≤6.5%) after 6 months of treatment
Original publication
β-hydroxybutyrate as a biomarker of β-cell function in new-onset type 2 diabetes and its association with treatment response at 6 months. Diabetes Metab. Published 25 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →